A first-in-the-world clinical trial taking place at the Hadassah Medical Organization will directly test whether the Bacillus Calmette-Guérin (BCG) vaccine –– developed over 100 years ago to prevent tuberculosis –– should be widely administered in the fight against Alzheimer’s.
Previous studies, at Hadassah and at other hospitals around the world, have found that administering the BCG vaccine may reduce the risk of developing Alzheimer’s disease by strengthening the immune system.The clinical trial will evaluate if the BCG vaccination reduces the level of phosphorylated tau protein and other biomarkers in the blood and thus helps prevent the development of dementia.
Read more in The Jerusalem Post as Barbara Sofer, public relations director at the Hadassah Offices in Israel, writes about what it’s like to participate in this clinical trial.
Read More
Video: Re-thinking Alzheimer's DIsease with Hadassah's Prof. Tamir Ben-Hur
Where are we with Alzheimer's? Hadassah Doctor Provides His Perspective
Hadassah Brain Mapping Has Important Implications for Early Alzheimer's Diagnosis